After a Speedy IPO, Equillium Expands Antibody R&D to Renal Disease

After a Speedy IPO, Equillium Expands Antibody R&D to Renal Disease

Source: 
Xconomy
snippet: 

Equillium, a biotech that’s looking to develop an antibody drug for immuno-inflammatory diseases, has added a form of renal disease to the indications for which it aims to develop medicines.